Tap a claim on the ring to put it at the centre.
← No technology, including drug discovery technologies, is immune to the eventual pull toward commoditization.
17 connected korrents · 18 moments from 8 Mar 2012 to 10 Aug 2026.
Everything filed under AI and science
AI and science
Everything filed under LLMs
LLMs
Everything filed under mathematics
mathematics
Everything filed under protein structure prediction
protein structure prediction
Everything filed under innovation
innovation
Everything filed under infrastructure
infrastructure
Everything filed under design
design
Everything filed under venture capital
venture capital Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Read this korrent: No technology, including drug discovery technologies, is immune to the eventual pull toward commoditization. No technology, including drug discovery technologies, is immune to the eventual pull toward commoditization. Last stated 2 years ago
16 Mar 2025
EH
Elliot Hershberg — holds since 2025-03-16 — tap for who they are
Same subject: AI infrastructure companies that sell tools rather than drugs can become massive, highly valuable businesses in biotech. — tap to centre the map on it AI infrastructure companies that sell tools rather than drugs can become massive, highly valuable businesses in biotech. Last stated 10 months ago
23 Nov 2025
EH
Elliot Hershberg — holds since 2025-11-23 — tap for who they are
Same subject: A country cannot have radical technological breakthroughs and also refuse to tolerate uncomfortably rich people, because the financial system it resents is what funds the innovation. — tap to centre the map on it A country cannot have radical technological breakthroughs and also refuse to tolerate uncomfortably rich people, because the financial system it resents is what funds the innovation. Last stated a year ago
13 Aug 2025
KJ
Keyu Jin — holds since 2025-08-13 — tap for who they are
Same subject: The hard part of drug discovery is knowing what to make - which target is worth drugging - not designing the molecule. — tap to centre the map on it The hard part of drug discovery is knowing what to make - which target is worth drugging - not designing the molecule. Last stated 2 months ago
21 Jul 2026
AT
Alex Telford — holds since 2023-12-23 — tap for who they are
RT
Ruxandra Teslo — holds since 2026-07-21 — tap for who they are
Same subject: Every new drug has to beat the cheap generics that came before it, and that competition with our own back catalogue is why drug discovery gets harder over time. — tap to centre the map on it Every new drug has to beat the cheap generics that came before it, and that competition with our own back catalogue is why drug discovery gets harder over time. Last stated 15 years ago
8 Mar 2012
DL
Derek Lowe — holds since 2012-03-08 — tap for who they are
Same subject: New technologies can meaningfully improve R&D productivity in drug development. — tap to centre the map on it New technologies can meaningfully improve R&D productivity in drug development. Last stated 6 months ago
12 Apr 2026
EH
Elliot Hershberg — holds since 2026-04-12 — tap for who they are
Same subject: Drug discovery has become less efficient over time despite continued technological progress. — tap to centre the map on it Drug discovery has become less efficient over time despite continued technological progress. Last stated 8 months ago
18 Jan 2026
EH
Elliot Hershberg — holds since 2026-01-18 — tap for who they are
Same subject: Investment will keep draining out of cell and gene therapy until manufacturing and regulatory risk become possible to underwrite. — tap to centre the map on it Investment will keep draining out of cell and gene therapy until manufacturing and regulatory risk become possible to underwrite. Last stated 4 months ago
10 Jun 2026
RT
Ruxandra Teslo — holds since 2026-06-10 — tap for who they are
Same subject: A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. — tap to centre the map on it A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. Last stated 2 years ago
13 May 2024
DL
Derek Lowe — holds since 2024-05-13 — tap for who they are
Same subject: A narrow, highly accurate model can beat a general one inside its own domain, as AlphaFold did, and materials science and chip design are next. — tap to centre the map on it A narrow, highly accurate model can beat a general one inside its own domain, as AlphaFold did, and materials science and chip design are next. Last stated 2 months ago
30 Jul 2026
JD
Jeff Dean — holds since 2026-07-30 — tap for who they are
Same subject: Contemporary physical and evolutionary structure-prediction approaches fall far short of experimental accuracy without a close experimental homologue, limiting biological utility. — tap to centre the map on it Contemporary physical and evolutionary structure-prediction approaches fall far short of experimental accuracy without a close experimental homologue, limiting biological utility. Last stated 5 years ago
15 Jul 2021
DH
Demis Hassabis — holds since 2021-07-15 — tap for who they are
Same subject: Deep learning has effectively solved the problem of predicting a protein's 3D structure from its sequence. — tap to centre the map on it Deep learning has effectively solved the problem of predicting a protein's 3D structure from its sequence. Last stated a year ago
29 Jun 2025
EH
Elliot Hershberg — holds since 2025-06-29 — tap for who they are
Same subject: A badly written AI outbound email is evidence of a bad vendor, not of a limit of AI. — tap to centre the map on it A badly written AI outbound email is evidence of a bad vendor, not of a limit of AI. Last stated 9 months ago
1 Jan 2026
JL
Jason Lemkin — holds since 2026-01-01 — tap for who they are
Same subject: A bigger context window does not give you a smarter model; the intelligence of the model is what decides how much of that window it can actually attend to. — tap to centre the map on it A bigger context window does not give you a smarter model; the intelligence of the model is what decides how much of that window it can actually attend to. Last stated 3 months ago
15 Jul 2026
DH
Dex Horthy — holds since 2026-07-15 — tap for who they are
Same subject: A child who has seen ten cats learns what a machine needs the whole internet of cat photos for, by a learning pathway nobody has solved. — tap to centre the map on it A child who has seen ten cats learns what a machine needs the whole internet of cat photos for, by a learning pathway nobody has solved. Last stated 2 months ago
10 Aug 2026
FL
Fei-Fei Li — holds since 2026-08-10 — tap for who they are
Same subject: A persistently rising dividend yield eventually forces capital appreciation as the market rerates the stock. — tap to centre the map on it A persistently rising dividend yield eventually forces capital appreciation as the market rerates the stock. Last stated 7 months ago
3 Mar 2026
SB
Sanjay Bakshi — holds since 2026-03-03 — tap for who they are
Same subject: A proof and an explanation are different things, and a theorem can stay an unsolved expository problem long after it is proved. — tap to centre the map on it A proof and an explanation are different things, and a theorem can stay an unsolved expository problem long after it is proved. Last stated 3 months ago
30 Jun 2026
GS
Grant Sanderson — holds since 2026-06-30 — tap for who they are
Same subject: A stream of AI-written papers with any error rate at all becomes insufferable, because finding the error costs more than the paper is worth even at ninety-nine percent. — tap to centre the map on it A stream of AI-written papers with any error rate at all becomes insufferable, because finding the error costs more than the paper is worth even at ninety-nine percent. Last stated 3 months ago
30 Jun 2026
GS
Grant Sanderson — holds since 2026-06-30 — tap for who they are
At the centre
No technology, including drug discovery technologies, is immune to the eventual pull toward commoditization.
Holds Read this korrent →
AI infrastructure companies that sell tools rather than drugs can become massive, highly valuable businesses in biotech.
Holds
A country cannot have radical technological breakthroughs and also refuse to tolerate uncomfortably rich people, because the financial system it resents is what funds the innovation.
Holds
The hard part of drug discovery is knowing what to make - which target is worth drugging - not designing the molecule.
Holds
Every new drug has to beat the cheap generics that came before it, and that competition with our own back catalogue is why drug discovery gets harder over time.
Holds
New technologies can meaningfully improve R&D productivity in drug development.
Holds
Drug discovery has become less efficient over time despite continued technological progress.
Holds
Investment will keep draining out of cell and gene therapy until manufacturing and regulatory risk become possible to underwrite.
Holds
A compound's AI origin story is not by itself a reason to expect it to do better in the clinic.
Holds
A narrow, highly accurate model can beat a general one inside its own domain, as AlphaFold did, and materials science and chip design are next.
Holds
Contemporary physical and evolutionary structure-prediction approaches fall far short of experimental accuracy without a close experimental homologue, limiting biological utility.
Holds
Deep learning has effectively solved the problem of predicting a protein's 3D structure from its sequence.
Holds
A badly written AI outbound email is evidence of a bad vendor, not of a limit of AI.
Holds
A bigger context window does not give you a smarter model; the intelligence of the model is what decides how much of that window it can actually attend to.
Holds
A child who has seen ten cats learns what a machine needs the whole internet of cat photos for, by a learning pathway nobody has solved.
Holds
A persistently rising dividend yield eventually forces capital appreciation as the market rerates the stock.
Holds
A proof and an explanation are different things, and a theorem can stay an unsolved expository problem long after it is proved.
Holds
A stream of AI-written papers with any error rate at all becomes insufferable, because finding the error costs more than the paper is worth even at ninety-nine percent.
Holds